Daratumumab for Antibody Mediated Rejection in Lung Transplant

Introduction: Antibody-mediated rejection (AMR) in lung transplantation is associated with chronic lung allograft dysfunction and decreased survival. Current treatment modalities for AMR include corticosteroids, plasmapheresis, intravenous immunoglobulin (IVIG), B-cell depleting agents and proteasome inhibitors, all with variable clinical responses. Daratumumab is a monoclonal antibody that targets CD-38 on plasma cells resulting in complement-dependent cytotoxicity, antibody-dependent phagocytosis, and apoptosis.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Source Type: research